礼来将收购Ajax Therapeutics，以改善骨髓纤维化和真性红细胞增多症患者的治疗效果

发布时间：2026-04-27来源：礼来

Ajax's

阿贾克斯的

lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026

先导项目AJ1-11095是一款同类首创的II型JAK2抑制剂，目前正处于I期临床开发阶段，首次概念验证临床数据预计将在2026年下半年公布。

Based on its unique mode of binding JAK2, AJ1-11095 has the potential to deliver deeper and more durable disease control than approved therapies for myelofibrosis and polycythemia vera

基于其独特的JAK2结合模式，AJ1-11095有潜力比已批准的骨髓纤维化和真性红细胞增多症疗法提供更深入和更持久的疾病控制。

Acquisition builds on Lilly's established capabilities in blood cancers

收购建立在礼来在血癌领域已有的能力之上。

INDIANAPOLIS

印第安纳波利斯

and

和

NEW YORK

纽约

and

和

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

April 27, 2026

2026年4月27日

/PRNewswire/ --

Eli Lilly and Company

礼来公司

(NYSE: LLY) and

(NYSE: LLY) 和

Ajax Therapeutics, Inc.

阿贾克斯治疗学公司

('Ajax'), a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Lilly to acquire Ajax.

Ajax是一家为骨髓增生性肿瘤（MPNs）患者开发下一代JAK抑制剂的生物制药公司，该公司今天宣布了礼来收购Ajax的最终协议。

Ajax's

阿贾克斯的

lead asset, AJ1-11095, is an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 clinical trial, AJX-101, in patients with myelofibrosis who have previously been treated with a Type I JAK2 inhibitor.

领先资产AJ1-11095是一种研究性的一天一次口服、首创新药的II型JAK2抑制剂，目前正在进行一项I期临床试验（AJX-101），用于治疗先前接受过I型JAK2抑制剂治疗的骨髓纤维化患者。

All approved JAK2 inhibitors for patients with MPNs,

所有获批用于治疗MPNs患者的JAK2抑制剂，

including myelofibrosis and polycythemia vera, bind the Type I confirmation of JAK2. While these JAK2 inhibitors provide clinical and symptomatic relief, many patients often discontinue Type I JAK2 treatment due to a lack of durable benefit or loss of response.

包括骨髓纤维化和真性红细胞增多症在内的疾病，会结合JAK2的I型构象。尽管这些JAK2抑制剂能够提供临床和症状上的缓解，许多患者常常由于缺乏持久的疗效或失去反应而停止I型JAK2治疗。

AJ1-11095 was designed as a selective Type II JAK2 inhibitor

AJ1-11095 被设计为一种选择性的 II 型 JAK2 抑制剂。

to not only deliver deeper and more durable efficacy than existing JAK2 inhibitors but also to provide a novel treatment option for those patients who become resistant to Type I JAK2

不仅要提供比现有的JAK2抑制剂更深、更持久的疗效，还要为那些对I型JAK2产生耐药性的患者提供一种新的治疗选择。

inhibitors. The Phase 1 clinical trial of AJ1-11095 began in late 2024 and dose selection for future clinical development is expected in 2026.

抑制剂。AJ1-11095 的一期临床试验于 2024 年底开始，预计 2026 年将进行未来临床开发的剂量选择。

'As a founding strategic investor in Ajax, Lilly has long believed in the approach and is excited about the potential for AJ1-11095 to deliver deeper and more durable efficacy than available treatments with a tolerability profile that would allow for patients to remain on therapy longer and be used across both the first- and second-line settings,' said .

“作为阿贾克斯的创始战略投资者，礼来长期以来一直相信这种方法，并对AJ1-11095的潜力感到兴奋，它可能比现有治疗方法带来更深入、更持久的疗效，且其耐受性特点能够让患者持续接受治疗更长时间，并在一线和二线环境中使用，”

Jacob Van Naarden

雅各布·范·纳登

, executive vice president and president of Lilly Oncology and head of corporate business development. 'We look forward to the presentation of clinical proof-of-concept data later in 2026, rapidly advancing AJ1-11095 into registrational clinical trials, and using our expertise in blood cancer to hopefully deliver another important new medicine to patients and hematologists.'.

，执行副总裁兼礼来肿瘤学总裁以及公司业务发展主管。“我们期待在2026年底展示临床概念验证数据，迅速将AJ1-11095推进到注册临床试验，并利用我们在血癌方面的专业知识，希望能为患者和血液科医生带来另一种重要的新药。”

'We started Ajax to build on the work of its five scientific founders, including Ross Levine, MD, chief scientific officer at

“我们创立了Ajax公司，以在其五位科学创始人（包括罗斯·莱文（Ross Levine），医学博士，首席科学官）的工作基础上继续发展，

Memorial Sloan Kettering Cancer Center

纪念斯隆凯特琳癌症中心

and chair of

和主席

Ajax's

阿贾克斯的

scientific advisory board, who sought to develop a novel class of selective and more potent JAK2 inhibitors to address the significant unmet need of patients with MPNs,' said

科学顾问委员会表示，他们试图开发一类新型的选择性更强、效力更高的JAK2抑制剂，以满足MPNs患者显著未满足的需求。

Martin Vogelbaum

马丁·沃格尔鲍姆

, co-founder and chief executive officer of Ajax Therapeutics. 'With a small but highly motivated team, we have successfully applied this work to the design and development of our highly selective, first-in-class Type II JAK2 inhibitor, AJ1-11095. We now look forward to Lilly advancing AJ1-11095 through the clinic and providing a much-needed new therapy for patients with MPNs. It has been an honor working with our employees and scientific advisors and we're grateful to our clinical investigators, and most importantly, the patients who have participated in our ongoing Phase 1 study, AJX-101.'.

Ajax Therapeutics的联合创始人兼首席执行官表示：“凭借一个规模虽小但高度积极的团队，我们已成功将这项工作应用于我们高选择性、首创的II型JAK2抑制剂AJ1-11095的设计与开发。我们现在期待礼来公司推动AJ1-11095通过临床试验，为骨髓增生性肿瘤（MPNs）患者提供一种迫切需要的新疗法。与我们的员工和科学顾问合作是一种荣幸，我们感谢参与我们正在进行的I期研究AJX-101的临床研究人员，最重要的是，感谢参与研究的患者。”

Under the terms of the agreement, Lilly will acquire Ajax and Ajax shareholders could receive up to

根据协议条款，礼来公司将收购阿贾克斯公司，阿贾克斯公司的股东们最多可获得

$2.3 billion

23亿美元

in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.

现金支付，包括首付款以及在达成某些临床和监管里程碑后的后续付款。

The transaction is subject to customary closing conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Lilly will determine the accounting treatment of this transaction following closing in accordance with Generally Accepted Accounting Principles (GAAP). This transaction will thereafter be reflected in Lilly's financial results and financial guidance..

该交易需符合惯例的交割条件，包括依据1976年《哈特-斯科特-罗迪诺反托拉斯改进法》获得批准。礼来公司将按照公认会计原则 (GAAP)，在交割后确定该交易的会计处理方式。此后，该交易将反映在礼来的财务结果和财务指引中。

For

为了

Lilly Ropes Gray LLP

莉莉·罗普斯·格雷律师事务所

is acting as legal counsel. For Ajax,

正在担任法律顾问。对于阿贾克斯，

Cooley LLP

科利律师事务所

is acting as legal counsel.

担任法律顾问。

Kirkland & Ellis LLP

柯克兰和艾利斯律师事务所

also provided legal advice to Ajax.

还为阿贾克斯提供了法律咨询。

About Ajax Therapeutics

关于Ajax Therapeutics

Ajax Therapeutics, Inc.

阿贾克斯治疗学公司

is pursuing uniquely selective approaches to develop novel next generation therapies for myeloproliferative neoplasms (MPNs), including myelofibrosis. By combining the deep cancer and structural biology insights of our founding scientists with the industry's most advanced computational structure-based drug discovery platforms .

正在追求独特且有针对性的方法，以开发用于骨髓增殖性肿瘤（MPNs）的新型下一代疗法，包括骨髓纤维化。通过将我们创始科学家深厚的癌症和结构生物学见解与行业最先进的基于计算结构的药物发现平台相结合。

from our founding collaboration partner, Schrödinger, Inc,

来自我们的创始合作合作伙伴薛定谔公司，

we aim to discover and develop more precisely designed therapies to address the significant unmet needs for patients with MPNs. For more information, please visit

我们旨在发现和开发更精确设计的疗法，以满足MPN患者的重大未满足需求。欲了解更多信息，请访问

www.ajaxtherapeutics.com

。

About Lilly

莉莉简介

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家医药公司，将科学转化为治疗手段，以改善世界各地人们的生活。近150年来，我们一直致力于开创改变生命的发现，如今我们的药物已帮助全球数千万人。通过利用生物技术、化学和基因医学的力量，我们的科学家正在加速推进新的发现，以解决一些全球最重要的健康挑战：重新定义糖尿病护理；治疗肥胖症并遏制其最具破坏性的长期影响；推动对抗阿尔茨海默病的斗争；为一些最严重的免疫系统疾病提供解决方案；并将最难治疗的癌症转变为可管理的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit .

每迈向更健康的世界一步，我们都受到一个目标的驱使：让数百万人的生活更美好。这包括开展反映世界多样性的创新临床试验，并努力确保我们的药物可及且负担得起。欲了解更多信息，请访问。

Lilly.com

莉莉网

and

和

Lilly.com/news

Lilly.com/新闻

, or follow us on

，或者关注我们

Facebook

脸书

，

Instagram

, and

，以及

领英

. F-LLY

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of Ajax Therapeutics and

本新闻稿包含关于礼来公司收购 Ajax Therapeutics 的好处的前瞻性陈述（该术语定义见 1995 年《私人证券诉讼改革法案》）以及

Ajax's

阿贾克斯的

product candidate for oncology, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in closing and implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will close the transaction or realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this release, or that the acquisition will yield commercially successful products.

用于肿瘤学的产品候选者，反映了礼来公司当前的信念和期望。然而，像任何此类行动一样，在完成和实施收购以及药物研究、开发和商业化的进程中，存在重大风险和不确定性。尤其是，无法保证礼来公司将完成交易或实现收购的预期效益，无法保证收购将实现本公告中讨论的结果，也无法保证收购将产生商业上成功的产品。

For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the .

有关这些可能导致实际结果与礼来公司预期不同的风险和其他不确定性的进一步讨论，请参阅礼来公司向美国证券交易委员会提交的Form 10-K和Form 10-Q报告。

United States Securities and Exchange Commission

美国证券交易委员会

. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

除非法律要求，礼来公司没有义务更新前瞻性声明以反映本发布日期之后的事件。

Refer to:

参考：

Ashley Hennessey;

阿什利·亨尼西；

gentry_ashley_jo@lilly.com

; 317-416-4363 (Media)

；317-416-4363（媒体）

Michael Czapar;

迈克尔·查帕尔；

czapar_michael_c@lilly.com

; 317-617-0983 (Investors)

；317-617-0983（投资者）

Kathryn Morris;

凯瑟琳·莫里斯；

kathryn@theyatesnetwork.com

凯瑟琳@theyatesnetwork.com

; 914-204-6412 (Ajax Media)

；914-204-6412（Ajax Media）

View original content to download multimedia:

查看原始内容以下载多媒体：

https://www.prnewswire.com/news-releases/lilly-to-acquire-ajax-therapeutics-to-advance-outcomes-for-patients-with-myelofibrosis-and-polycythemia-vera-302753832.html

SOURCE

源代码

Eli Lilly and Company

礼来公司

转载说明：本文系转载内容，版权归原作者及原出处所有。转载目的在于传递更多行业信息，文章观点仅代表原作者本人，与本平台立场无关。若涉及作品版权问题，请原作者或相关权利人及时与本平台联系，我们将在第一时间核实后移除相关内容。